Search

Your search keyword '"Lupi,Alessio"' showing total 23 results
Start Over Author "Lupi,Alessio"
23 results on '"Lupi,Alessio"'

1. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment

Author

Pretta, Andrea, Ziranu, Pina, Giampieri, Riccardo, Donisi, Clelia, Cimbro, Erika, Spanu, Dario, Lai, Eleonora, Pecci, Federica, Balconi, Francesca, Lupi, Alessio, Pozzari, Marta, Persano, Mara, Murgia, Sara, Pusceddu, Valeria, Puzzoni, Marco, Berardi, Rossana, and Scartozzi, Mario

Published
2023
Full Text
View/download PDF

2. Clinical and prognostic characteristics of early onset metastatic pancreatic cancer.

Author

Pretta, Andrea, primary, Giampieri, Riccardo, additional, Nichetti, Federico, additional, Ziranu, Pina, additional, Lupi, Alessio, additional, Cimbro, Erika, additional, Andena, Paola, additional, Felicetti, Cristiano, additional, Pircher, Chiara Carlotta, additional, Gusmaroli, Eleonora, additional, Donisi, Clelia, additional, Balconi, Francesca, additional, Mariani, Stefano, additional, Lai, Eleonora, additional, Puzzoni, Marco, additional, Pusceddu, Valeria, additional, Berardi, Rossana, additional, Niger, Monica, additional, and Scartozzi, Mario, additional

Published
2024
Full Text
View/download PDF

3. Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma.

Author

Pretta, Andrea, primary, Giampieri, Riccardo, additional, Nichetti, Federico, additional, Ziranu, Pina, additional, Lupi, Alessio, additional, Moledda, Giusy, additional, Andena, Paola, additional, Felicetti, Cristiano, additional, D'Agata, Alessandra Pia, additional, Pircher, Chiara Carlotta, additional, Codipietro, Claudia, additional, Rota, Simone, additional, Rizzo, Daiana, additional, Sanna, Giorgia, additional, Lai, Eleonora, additional, Puzzoni, Marco, additional, Pusceddu, Valeria, additional, Berardi, Rossana, additional, Niger, Monica, additional, and Scartozzi, Mario, additional

Published
2024
Full Text
View/download PDF

6. Safety of extended interval dosing immune checkpoint inhibitors:a multicenter cohort study

Author

Cantini, Luca, Paoloni, Francesco, Pecci, Federica, Spagnolo, Francesco, Genova, Carlo, Tanda, Enrica Teresa, Aerts, Sophie, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Zoratto, Federica, Fancelli, Sara, Lupi, Alessio, Della Corte, Carminia Maria, Parisi, Alessandro, Bennati, Chiara, Ortega, Cinzia, Atzori, Francesco, Piovano, Pier Luigi, Orciuolo, Corrado, De Tursi, Michele, Ghidini, Michele, Botticelli, Andrea, Scagnoli, Simone, Belluomini, Lorenzo, Leporati, Rita, Veccia, Antonello, Di Giacomo, Anna Maria, Festino, Lucia, Cortinovis, Diego, Acquati, Mirko, Filetti, Marco, Giusti, Raffaele, Tucci, Marco, Sergi, Maria Chiara, Garutti, Mattia, Puglisi, Fabio, Manglaviti, Sara, Citarella, Fabrizio, Santoni, Matteo, Rijavec, Erika, Lo Russo, Giuseppe, Santini, Daniele, Addeo, Alfredo, Antonuzzo, Lorenzo, Indini, Alice, Rocchi, Marco Bruno Luigi, Cortellini, Alessio, Grossi, Francesco, Ascierto, Paolo Antonio, Aerts, Joachim G.J.V., Berardi, Rossana, Cantini, Luca, Paoloni, Francesco, Pecci, Federica, Spagnolo, Francesco, Genova, Carlo, Tanda, Enrica Teresa, Aerts, Sophie, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Zoratto, Federica, Fancelli, Sara, Lupi, Alessio, Della Corte, Carminia Maria, Parisi, Alessandro, Bennati, Chiara, Ortega, Cinzia, Atzori, Francesco, Piovano, Pier Luigi, Orciuolo, Corrado, De Tursi, Michele, Ghidini, Michele, Botticelli, Andrea, Scagnoli, Simone, Belluomini, Lorenzo, Leporati, Rita, Veccia, Antonello, Di Giacomo, Anna Maria, Festino, Lucia, Cortinovis, Diego, Acquati, Mirko, Filetti, Marco, Giusti, Raffaele, Tucci, Marco, Sergi, Maria Chiara, Garutti, Mattia, Puglisi, Fabio, Manglaviti, Sara, Citarella, Fabrizio, Santoni, Matteo, Rijavec, Erika, Lo Russo, Giuseppe, Santini, Daniele, Addeo, Alfredo, Antonuzzo, Lorenzo, Indini, Alice, Rocchi, Marco Bruno Luigi, Cortellini, Alessio, Grossi, Francesco, Ascierto, Paolo Antonio, Aerts, Joachim G.J.V., and Berardi, Rossana

Abstract

BACKGROUND: Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. METHODS: Characteristics of 812 consecutive solid cancer patients who received at least 1 cycle of ED monotherapy (pembrolizumab 400 mg Q6W or nivolumab 480 mg Q4W) after switching from canonical interval dosing (CD; pembrolizumab 200 mg Q3W or nivolumab 240 mg Q2W) or treated upfront with ED were retrieved. The primary objective was to compare irAEs patterns within the same population (before and after switch to ED). irAEs spectrum in patients treated upfront with ED and association between irAEs and overall survival were also described. RESULTS: A total of 550 (68%) patients started ICIs with CD and switched to ED. During CD, 225 (41%) patients developed any grade and 17 (3%) G3 or G4 irAEs; after switching to ED, any grade and G3 or G4 irAEs were experienced by 155 (36%) and 20 (5%) patients. Switching to ED was associated with a lower probability of any grade irAEs (adjusted odds ratio [aOR] = 0.83, 95% confidence interval [CI] = 0.64 to 0.99; P = .047), whereas no difference for G3 or G4 events was noted (aOR = 1.55, 95% CI = 0.81 to 2.94; P = .18). Among patients who started upfront with ED (n = 232, 32%), 107 (41%) developed any grade and 14 (5%) G3 or G4 irAEs during ED. Patients with irAEs during ED had improved overall survival (adjusted hazard ratio [aHR] = 0.53, 95% CI = 0.34 to 0.82; P = .004 after switching; aHR = 0.57, 95% CI = 0.35 to 0.93; P = .025 upfront). CONCLUSIONS: Switching ICI treatment from CD and ED did not increase the incidence of irAEs and represents a safe option also outside clinical trials.

Published
2023

7. Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers

Author

Parisi,Alessandro, Rossi,Francesca, De Filippis,Chiara, Paoloni,Francesco, Felicetti,Cristiano, Mammarella,Alex, Pecci,Federica, Lupi,Alessio, Berardi,Rossana, Parisi,Alessandro, Rossi,Francesca, De Filippis,Chiara, Paoloni,Francesco, Felicetti,Cristiano, Mammarella,Alex, Pecci,Federica, Lupi,Alessio, and Berardi,Rossana

Abstract

Alessandro Parisi, Francesca Rossi, Chiara De Filippis, Francesco Paoloni, Cristiano Felicetti, Alex Mammarella, Federica Pecci, Alessio Lupi, Rossana Berardi Department of Clinical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero Universitaria delle Marche, Ancona, 60126, ItalyCorrespondence: Rossana Berardi, Department of Medical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero Universitaria delle Marche, Ancona, 60126, Italy, Tel +39 715964169, Email r.berardi@staff.univpm.itAbstract: In recent years, poly (ADP-ribose) polymerase (PARP) inhibition has become a promising therapeutic option for several tumors, especially for those harboring a BRCA 1– 2 mutation or a deficit in the homologous recombination repair (HRR) pathway. Nevertheless, to date, PARP inhibitors are still not largely used for thoracic malignancies neither as a single agent nor in combination with other treatments. Recently, a deeper understanding of HRR mechanisms, alongside the development of new targeted and immunotherapy agents, particularly against HRR-deficient tumors, traced the path to new treatment strategies for many tumor types including lung cancer and malignant pleural mesothelioma. The aim of this review is to sum up the current knowledge about cancer-DNA damage response pathways inhibition and to update the status of recent clinical trials investigating the use of PARP inhibitors, either as monotherapy or in combination with other agents for the treatment of thoracic malignancies. We will also briefly discuss available evidence on Poly(ADP-Ribose) Glycohydrolase (PARG) inhibitors, a novel promising therapeutic option in oncology.Keywords: lung cancer, PARP inhibitors, PARG inhibitors, homologous recombination repair, malignant pleural mesothelioma, targeted treatment

Published
2023

8. Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study

Author

Cantini, Luca, primary, Paoloni, Francesco, additional, Pecci, Federica, additional, Spagnolo, Francesco, additional, Genova, Carlo, additional, Tanda, Enrica Teresa, additional, Aerts, Sophie, additional, Rebuzzi, Sara Elena, additional, Fornarini, Giuseppe, additional, Zoratto, Federica, additional, Fancelli, Sara, additional, Lupi, Alessio, additional, Della Corte, Carminia Maria, additional, Parisi, Alessandro, additional, Bennati, Chiara, additional, Ortega, Cinzia, additional, Atzori, Francesco, additional, Piovano, Pier Luigi, additional, Orciuolo, Corrado, additional, De Tursi, Michele, additional, Ghidini, Michele, additional, Botticelli, Andrea, additional, Scagnoli, Simone, additional, Belluomini, Lorenzo, additional, Leporati, Rita, additional, Veccia, Antonello, additional, Di Giacomo, Anna Maria, additional, Festino, Lucia, additional, Cortinovis, Diego, additional, Acquati, Mirko, additional, Filetti, Marco, additional, Giusti, Raffaele, additional, Tucci, Marco, additional, Sergi, Maria Chiara, additional, Garutti, Mattia, additional, Puglisi, Fabio, additional, Manglaviti, Sara, additional, Citarella, Fabrizio, additional, Santoni, Matteo, additional, Rijavec, Erika, additional, Lo Russo, Giuseppe, additional, Santini, Daniele, additional, Addeo, Alfredo, additional, Antonuzzo, Lorenzo, additional, Indini, Alice, additional, Rocchi, Marco Bruno Luigi, additional, Cortellini, Alessio, additional, Grossi, Francesco, additional, Ascierto, Paolo Antonio, additional, Aerts, Joachim G J V, additional, and Berardi, Rossana, additional

Published
2023
Full Text
View/download PDF

9. The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line.

Author

Pretta, Andrea, primary, Donisi, Clelia, additional, Giampieri, Riccardo, additional, Ziranu, Pina, additional, Cimbro, Erika, additional, Spanu, Dario, additional, Pecci, Federica, additional, Migliari, Marco, additional, Balconi, Francesca, additional, Lupi, Alessio, additional, Palmas, Enrico, additional, Deias, Giulia, additional, Congiu, Benedetta, additional, Pozzari, Marta, additional, Murgia, Sara, additional, Valeria, Pusceddu, additional, Puzzoni, Marco, additional, Lai, Eleonora, additional, Berardi, Rossana, additional, and Scartozzi, Mario, additional

Published
2023
Full Text
View/download PDF

11. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment

Author

Pretta, Andrea, primary, Ziranu, Pina, additional, Giampieri, Riccardo, additional, Donisi, Clelia, additional, Cimbro, Erika, additional, Spanu, Dario, additional, Lai, Eleonora, additional, Pecci, Federica, additional, Balconi, Francesca, additional, Lupi, Alessio, additional, Pozzari, Marta, additional, Persano, Mara, additional, Murgia, Sara, additional, Pusceddu, Valeria, additional, Puzzoni, Marco, additional, Berardi, Rossana, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

13. Influence of type 2 diabetes mellitus and concomitant anti-diabetic medications in patients with metastatic pancreatic ductal adenocarcinoma.

Author

Pretta, Andrea, primary, Cimbro, Erika, additional, Giampieri, Riccardo, additional, Spanu, Dario, additional, Lai, Eleonora, additional, Pecci, Federica, additional, Balconi, Francesca, additional, Lupi, Alessio, additional, Pozzari, Marta, additional, Murgia, Sara, additional, Bardanzellu, Fabio, additional, Maccioni, Antonio, additional, Contu, Fabiana, additional, Persano, Mara, additional, Donisi, Clelia, additional, Pusceddu, Valeria, additional, Puzzoni, Marco, additional, Ziranu, Pina, additional, Berardi, Rossana, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

14. Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy.

Author

Pretta, Andrea, primary, Spanu, Dario, additional, Giampieri, Riccardo, additional, Lai, Eleonora, additional, Cimbro, Erika, additional, Pecci, Federica, additional, Balconi, Francesca, additional, Lupi, Alessio, additional, Pozzari, Marta, additional, Murgia, Sara, additional, Bardanzellu, Fabio, additional, Maccioni, Antonio, additional, Contu, Fabiana, additional, Persano, Mara, additional, Donisi, Clelia, additional, Valeria, Pusceddu, additional, Puzzoni, Marco, additional, Ziranu, Pina, additional, Berardi, Rossana, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

15. Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients

Author

Mariani, Stefano, primary, Puzzoni, Marco, additional, Giampieri, Riccardo, additional, Ziranu, Pina, additional, Pusceddu, Valeria, additional, Donisi, Clelia, additional, Persano, Mara, additional, Pinna, Giovanna, additional, Cimbro, Erika, additional, Parrino, Alissa, additional, Spanu, Dario, additional, Pretta, Andrea, additional, Lai, Eleonora, additional, Liscia, Nicole, additional, Lupi, Alessio, additional, Giglio, Enrica, additional, Palomba, Grazia, additional, Casula, Milena, additional, Pisano, Marina, additional, Palmieri, Giuseppe, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

17. Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

Author

Giampieri, Riccardo, primary, Lupi, Alessio, additional, Ziranu, Pina, additional, Bittoni, Alessandro, additional, Pretta, Andrea, additional, Pecci, Federica, additional, Persano, Mara, additional, Giglio, Enrica, additional, Copparoni, Cecilia, additional, Crocetti, Sonia, additional, Mandolesi, Alessandra, additional, Faa, Gavino, additional, Coni, Pierpaolo, additional, Scartozzi, Mario, additional, and Berardi, Rossana, additional

Published
2021
Full Text
View/download PDF

18. Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis

Author

Lenci, Edoardo, primary, Marcantognini, Giulia, additional, Cognigni, Valeria, additional, Lupi, Alessio, additional, Rinaldi, Silvia, additional, Cantini, Luca, additional, Fiordoliva, Ilaria, additional, Carloni, Anna Lisa, additional, Rocchi, Marco, additional, Zuccatosta, Lina, additional, Gasparini, Stefano, additional, and Berardi, Rossana, additional

Published
2021
Full Text
View/download PDF

19. Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy

Author

Cantini, Luca, primary, Bastianelli, Lucia, additional, Lupi, Alessio, additional, Pinterpe, Giada, additional, Pecci, Federica, additional, Belletti, Giovanni, additional, Stoico, Rosa, additional, Vitarelli, Francesca, additional, Moretti, Marco, additional, Onori, Nicoletta, additional, Giampieri, Riccardo, additional, Rocchi, Marco Bruno Luigi, additional, and Berardi, Rossana, additional

Published
2021
Full Text
View/download PDF

20. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab

Author

Lenci, Edoardo, primary, Cantini, Luca, additional, Pecci, Federica, additional, Cognigni, Valeria, additional, Agostinelli, Veronica, additional, Mentrasti, Giulia, additional, Lupi, Alessio, additional, Ranallo, Nicoletta, additional, Paoloni, Francesco, additional, Rinaldi, Silvia, additional, Nicolardi, Linda, additional, Caglio, Andrea, additional, Aerts, Sophie, additional, Cortellini, Alessio, additional, Ficorella, Corrado, additional, Chiari, Rita, additional, Di Maio, Massimo, additional, Dingemans, Anne-Marie C., additional, Aerts, Joachim G. J. V., additional, and Berardi, Rossana, additional

Published
2021
Full Text
View/download PDF

21. Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer

Author

Bittoni, Alessandro, primary, Pecci, Federica, additional, Mentrasti, Giulia, additional, Crocetti, Sonia, additional, Lupi, Alessio, additional, Lanese, Andrea, additional, Pellei, Chiara, additional, Ciotti, Chiara, additional, Cantini, Luca, additional, Giampieri, Riccardo, additional, Lenci, Edoardo, additional, Giglio, Enrica, additional, Bini, Federica, additional, Copparoni, Cecilia, additional, Meletani, Tania, additional, Baleani, Maria Giuditta, additional, and Berardi, Rossana, additional

Published
2021
Full Text
View/download PDF

22. Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing

Author

Giampieri, Riccardo, primary, Cantini, Luca, additional, Giglio, Enrica, additional, Bittoni, Alessandro, additional, Lanese, Andrea, additional, Crocetti, Sonia, additional, Pecci, Federica, additional, Copparoni, Cecilia, additional, Meletani, Tania, additional, Lenci, Edoardo, additional, Lupi, Alessio, additional, Baleani, Maria Giuditta, additional, and Berardi, Rossana, additional

Published
2020
Full Text
View/download PDF

23. Process analysis in thermal process engineering with high-performance computing using the example of grate firing

Author

University of Luxembourg: Luxembourg XDEM Research Centre - LuXDEM [research center], University of Luxembourg - UL [sponsor], Peters, Bernhard, Rousset, Alban, Besseron, Xavier, Mainassara Chekaraou, Abdoul Wahid, Gallo, Maria Grazia, Sansone, Franco, Lupi, Alessio, Galleti, Chiara, University of Luxembourg: Luxembourg XDEM Research Centre - LuXDEM [research center], University of Luxembourg - UL [sponsor], Peters, Bernhard, Rousset, Alban, Besseron, Xavier, Mainassara Chekaraou, Abdoul Wahid, Gallo, Maria Grazia, Sansone, Franco, Lupi, Alessio, and Galleti, Chiara

Abstract

Biomass as a renewable energy source continues to grow in popularity to reduce fossil fuel consumption for environmental and economic benefits. In the present contribution, the combustion chamber of a 16 MW geothermal steam super-heater, which is part of the Enel Green Power "Cornia 2" power plant, is being investigated with high-performance computing methods. For this purpose, the extended discrete element method (XDEM) developed at the University of Luxembourg is used in a high-performance computing environment, which includes both the moving wooden bed and the combustion chamber above it. The XDEM simulation platform is based on a hybrid four-way coupling between the Discrete Element Method (DEM) and Computational Fluid Dynamics (CFD). In this approach, particles are treated as discrete elements that are coupled by heat, mass, and momentum transfer to the surrounding gas as a continuous phase. For individual wood particles, besides the equations of motion, the differential conservation equations for mass, heat, and momentum are solved, which describe the thermodynamic state during thermal conversion. The consistency of the numerical results with the actual system performance is discussed in this paper to determine the potentials and limitations of the approach.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results